With some neu­ro tar­gets in mind, Ab­b­Vie gets So­sei's drug dis­cov­ery en­gine churn­ing again

Ab­b­Vie has got more work for So­sei Hep­tares.

A year and a half af­ter break­ing off a lega­cy Al­ler­gan pact in­volv­ing a slate of So­sei neu­rol­o­gy can­di­dates, Ab­b­Vie has drawn up a whole slew of new neu­ro tar­gets it wants to di­rect So­sei’s G pro­tein-cou­pled re­cep­tor ex­per­tise and struc­ture-based drug de­sign savvi­ness to­ward.

The heav­i­ly back-end­ed deal starts with a $40 mil­lion up­front and $40 mil­lion more in near-term mile­stones but is tied to biobucks adding up to $1.2 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER